1 JANUARY – 31 DECEMBER 2023
Continued strong growth and improved cash flow
NET SALES
EBITA
EARNINGS GROWTH
EBITA R12 MONTHS
P/WC
Strong cash flow and significant actions to improve profitability within Medtech
Demand is high in the markets and segments where AddLife's companies operate. We can now summarize 2023 as a year with historically strong organic growth of 10%. In the fourth quarter, cash flow improved significantly and net debt decreased by approximately SEK 400 million. Labtech's profitability was high and in Medtech, profitability was generally good, but weighed down by AddVision and Homecare, where we are now implementing significant measures to improve profitability.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
